Versican vs versikine: tolerance vs attack
In this issue of Blood, Hope et al demonstrate the differential influence of versican and its proteolytic derivate, versikine, on the immune system. This discovery opens a new avenue for immunotherapies in multiple myeloma patients.
Saved in:
| Main Author: | |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
4 August 2016
|
| In: |
Blood
Year: 2016, Volume: 128, Issue: 5, Pages: 612-613 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2016-06-721092 |
| Online Access: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1182/blood-2016-06-721092 Verlag, kostenfrei, Volltext: http://www.bloodjournal.org/content/128/5/612 
|
| Author Notes: | Michael Schmitt |
| Summary: | In this issue of Blood, Hope et al demonstrate the differential influence of versican and its proteolytic derivate, versikine, on the immune system. This discovery opens a new avenue for immunotherapies in multiple myeloma patients. |
|---|---|
| Item Description: | Gesehen am 22.03.2018 |
| Physical Description: | Online Resource |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2016-06-721092 |